Welcome to epgonline.org - the website for healthcare professionals

What's new?

  • ,Whats New LAL-D

    Launch of LAL-D Knowledge Centre

    A new educational resource on lysosomal acid lipase deficiency is
    now available to epgonline.org users. Content highlights include latest
    disease awareness facts and statistics, important treatment information and
    a video channel comprising expert discussions on topics such
    as diagnostic approach and current prognosis.

  • ,CSU news case studies 2016

    Updates to the Chronic Spontaneous
    Urticaria Knowledge Centre

    Case studies from urticaria experts Professor Christian Vestergaard
    and Professor Torsten Zuberbier have been added to the ‘Case Studies
    section of the Chronic Spontaneous Urticaria Knowledge Centre.
    Additionally, this resource has been updated with information
    on the TARGET My Hives app and refreshed with a whole new look and feel.

  • ,OAC Reversal Whats New 2

    Launch of Oral Anticoagulation Reversal Knowledge Centre

    This new resource provides healthcare professionals with accurate information on the approaches
    to oral anticoagulation reversal for patients who experience or are at risk of significant bleeding,
    or require surgery. View illustrated and referenced sections on management of bleeding, oral
    anticoagulants, symposium highlights, key publications commentary and more. This resource is
    developed by EPG Health Media (Europe) Ltd for epgonline.org in collaboration with CSL Behring, with
    content provided by CSL Behring.

    This resource is not intended for healthcare professionals outside Europe.

  • ,Hypogonadism Relaunch Whats New

    Launch of updated Hypogonadism Knowledge Centre

    Our Hypogonadism Knowledge Centre contains important disease awareness
    information to support healthcare professionals in the current best practice
    treatment and management of male hypogonadism and is available to access free of
    charge. Sections cover epidemiology, pathophysiology, signs and symptoms, treatment
    options, as well as useful resources and a regularly updated publications digest.

    G.MKT.GM.MH.01.2016.0364

  • ,Cystic Fibrosis Knowledge Centre

    Launch of the Cystic Fibrosis Knowledge Centre

    This new resource has been developed to support healthcare professionals
    in the treatment of patients with cystic fibrosis (CF).
    It contains a host of clinical information including a disease awareness section,
    emerging and supportive therapeutic options and current best practice
    based on recently updated guidelines by the
    European Cystic Fibrosis Society (ECFS).

Latest News

PB 272 (neratinib) filed with EU for breast cancer- Puma Biotechnology

28-Jun-2016

Puma Biotechnology has submitted its Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for PB 272 (neratinib). The potential indication is for the extended adjuvant treatment of HER2-positive early stage breast cancer ...

Phase III trial of Epidiolex (cannabidiol) meets primary endpoint in Lennox-Gastaut syndrome- GW Pharmaceuticals

28-Jun-2016

GW Pharmaceuticals has announced positive results of the first randomized, double-blind, placebo-controlled Phase III clinical trial of Epidiolex (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of ...

Astellas UK suspended from Association of the British Pharmaceutical Industry

28-Jun-2016

Astellas UK has been suspended from the Association of the British Pharmaceutical Industry. It has been accused of sending doctors on a free trip to Milan to discuss the UK launch of prostate cancer drug Xtandi. This suspension comes after five ...

Scenesse (afamelanotide 16mg) has its first launch in the Netherlands to treat erythropoietic protoporphyria.- Clinuvel Pharmaceuticals

27-Jun-2016

Clinuvel Pharmaceuticals Limited announced that its drug Scenesse (afamelanotide 16mg) has been launched in Europe, with the first commercial delivery of the product under European marketing authorisation. Patients with the rare genetic disorder ...

FDA Advisory panel to consider expanding the label of Jardiance (empagliflozin)to include reduction of CV risk in type 2 diabetes patients- Eli Lily + Boehringer

26-Jun-2016

An advisory panel to the FDA will be asked to vote next week on whether Jardiance (empagliflozin) from Eli Lilly & Co and Boehringer Ingelheim reduces the risk of cardiovascular death, according to documents posted on the agency's website. The ...

AstraZeneca will licence Byetta (exenatide) to Teva permitting launch in US of a generic in October 2017.

26-Jun-2016

Teva Pharmaceuticals USA, Inc.,announced that they have settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, LLC relating to AstraZeneca’s US Patent Nos. 6,858,576, 6,872,700, 6,956,026, ...

EU approves Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the treatment of HIV-1 infection.- Gilead Sciences

26-Jun-2016

Gilead Sciences, Inc.has announced that the European Commission has granted marketing authorization for the once-daily single tablet regimen (STR) Odefsey (emtricitabine 200 mg/rilpivirine 25 mg/tenofovir alafenamide 25 mg or R/F/TAF) for the ...

Recent Updates

Drugs

Clinical Guidelines

2016 European Guidelines on cardiovascular disease prevention in clinical practice

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

EASL Clinical Practice Guidelines on the management of benign liver tumours

EASL Clinical Practice Guidelines on the prevention, diagnosis and treatment of gallstones

Medical Journals

The impact of bariatric surgery on esophageal function.

Circulating Levels of the Adipokines Monocyte Chemotactic Protein-4 (MCP-4), Macrophage Inflammatory Protein-1β (MIP-1β), and Eotaxin-3 in Severe Obesity and Following Bariatric Surgery.

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

Cannabinoid receptor 2 as anti-obesity target: inflammation, fat storage and browning modulation.

epgonline.org Social

Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors